Welcome to our dedicated page for Canadian Pacific Kansas City SEC filings (Ticker: CP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating grain-car velocity metrics, cross-border capital spending, and hydrogen-locomotive costs inside Canadian Pacific Kansas City Limited’s voluminous SEC disclosures can take hours. Add multiple jurisdictions and you have one of rail’s most complex regulatory footprints.
Stock Titan eliminates that friction. Our AI reads every Canadian Pacific annual report 10-K simplified, each Canadian Pacific quarterly earnings report 10-Q filing, and every Canadian Pacific 8-K material events explained as soon as they hit EDGAR. You get plain-English summaries, red-flag alerts, and side-by-side comparisons that make understanding Canadian Pacific SEC documents with AI straightforward.
Need to track executive moves? The platform streams Canadian Pacific insider trading Form 4 transactions and Canadian Pacific Form 4 insider transactions real-time, so you can monitor when rail leadership buys or sells stock. Curious about network expansion budgets or segment revenue? Our Canadian Pacific earnings report filing analysis highlights grain, intermodal, and automotive trends quarter over quarter. Reviewing compensation? The Canadian Pacific proxy statement executive compensation section is distilled into key tables you can export in seconds.
All filings—10-K, 10-Q, 8-K, S-8, Form 4, Schedule 13D/G, and more—arrive with AI-powered summaries, keyword search, and historical charts. Whether you’re assessing fuel-efficiency milestones, merger integration costs, or Canadian Pacific executive stock transactions Form 4 details, Stock Titan surfaces the numbers that matter. Stop scrolling through 300-page PDFs; start seeing the railway’s story, update by update, on one page.
Sleep Number (SNBR) Q2 2025 10-Q highlights: Net sales fell 20% YoY to $327.9 million as retail comparable sales declined 19% and store count dropped to 630. Six-month sales decreased 18% to $721.2 million. Gross margin held at 59.1%, benefiting from 140 bp of product-cost savings offset by unfavorable mix and higher warranty/return costs.
Operating loss was $0.1 million (vs. $6.1 million profit LY) after $8.3 million of restructuring charges. Net loss widened to $25.0 million ($1.09 per diluted share); YTD loss is $33.7 million. Adjusted EBITDA slipped to $23.6 million from $28.3 million.
Cost-reduction program has generated $42.2 million cumulative charges and projects another ~$8 million in 2H 2025. Operating expenses were $42 million lower YoY, driven by 32% cut in media spend and lower incentive comp.
Balance sheet & liquidity: Cash was just $1.3 million; free cash flow burned $6.9 million YTD. Revolver borrowings rose to $563.9 million (7.9% weighted-avg rate), pushing leverage to 4.6×—just below the amended 4.75× covenant. The March 2025 credit amendment introduced a minimum $40 million liquidity covenant and step-down leverage/coverage targets through 2026; company remains compliant with $102 million revolver availability.
Outlook risks: sustained demand weakness in a multi-year mattress downturn, elevated interest costs, valuation allowance adding $14 million tax expense, further restructuring outlays, and pending California class-action litigation. Management is prioritizing margin initiatives, cash generation, and reduced capex ($8 million YTD) while evaluating impact of the newly enacted OBBBA tax law.
Merit Medical Systems (MMSI) – Q2 2025 10-Q highlights
- Revenue: $382.5 m, up 13.1 % YoY; six-month revenue $737.8 m, up 11.5 %.
- Mix: Cardiovascular +11 % to $364.0 m; Endoscopy devices +81 % to $18.4 m.
- Margins: Gross margin 48.3 % (+60 bp); SG&A +19 %, R&D +20 % drove operating margin down 130 bp to 12.3 %.
- Earnings: Net income $32.6 m (-8.8 %); diluted EPS $0.54 vs $0.61. 1H EPS $1.03 (-5.5 %).
- Cash flow: 1H operating cash flow $123.9 m (+18 %); capex $34.8 m; acquisitions $122.6 m.
- Balance sheet: Cash $341.8 m (-9 % YTD); long-term convertible notes $731.8 m; equity $1.49 bn (+7.9 %). Leverage covenants remain compliant.
- Acquisitions: Closed $126 m Biolife deal in May (hemostatic devices); prior Cook ($210 m) and EGS ($105 m) integrations ongoing. Goodwill now $504.6 m.
- Tax: Effective rate 24.9 % vs 22.1 %, pressuring earnings.
Overall, strong top-line growth and cash generation were offset by higher operating costs, acquisition spending and a rising tax rate, leading to lower YoY earnings.
FAQ
What is the current stock price of Canadian Pacific Kansas City (CP)?
What is the market cap of Canadian Pacific Kansas City (CP)?
What does Canadian Pacific Kansas City Limited (CPKC) do?
How does CPKC generate revenue?
What makes CPKC unique in the railway industry?
What sustainability initiatives has CPKC undertaken?
What commodities does CPKC transport?
What is the significance of the CPKC merger?
How does CPKC support cross-border trade?
What is the TempPro™ service offered by CPKC?
What partnerships does CPKC have to enhance its services?
What challenges does CPKC face in its operations?
